These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Proteasome inhibition in hematologic malignancies. Richardson PG; Hideshima T; Mitsiades C; Anderson K Ann Med; 2004; 36(4):304-14. PubMed ID: 15224657 [TBL] [Abstract][Full Text] [Related]
24. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma. Lee KW; Yun T; Song EK; Na II; Shin H; Bang SM; Lee JH; Lee ST; Kim JH; Yoon SS; Lee JS; Park S; Kim BK; Kim NK J Korean Med Sci; 2005 Aug; 20(4):598-62. PubMed ID: 16100450 [TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibition in the treatment of cancer. Richardson PG; Mitsiades C; Hideshima T; Anderson KC Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370 [TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Lara PN; Davies AM; Mack PC; Mortenson MM; Bold RJ; Gumerlock PH; Gandara DR Semin Oncol; 2004 Feb; 31(1 Suppl 1):40-6. PubMed ID: 14981579 [TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Leonard JP; Furman RR; Coleman M Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600 [TBL] [Abstract][Full Text] [Related]
32. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218 [TBL] [Abstract][Full Text] [Related]
34. Dissecting bortezomib: development, application, adverse effects and future direction. Cao B; Li J; Mao X Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134 [TBL] [Abstract][Full Text] [Related]
35. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Kelley TW; Alkan S; Srkalovic G; Hsi ED Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282 [TBL] [Abstract][Full Text] [Related]
36. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P Oncology; 2006; 70(6):474-82. PubMed ID: 17283449 [TBL] [Abstract][Full Text] [Related]
37. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma]. Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823 [TBL] [Abstract][Full Text] [Related]
39. Development of the proteasome inhibitor Velcade (Bortezomib). Adams J; Kauffman M Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612 [TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibition: a novel approach to cancer therapy. Adams J Trends Mol Med; 2002; 8(4 Suppl):S49-54. PubMed ID: 11927288 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]